Tianhe Sun,Zhiyu Huang,Wei-Ching Liang,Jianping Yin,Wei Yu Lin,Jia Wu,Jean-Michel Vernes,Jeff Lutman,Patrick Caplazi,Surinder Jeet,Tiffany Wong,Manda Wong,Daryle J. DePianto,Katrina B. Morshead,Kai-Hui Sun,Zora Modrusan,Jason A. Vander Heiden,Alexander R. Abbas,Hua Zhang,Min Xu,Elsa-Noah N'diaye,Meron Roose-Girma,Paul J. Wolters,Rajbharan Yadav,Siddharth Sukumaran,Nico Ghilardi,Racquel Corpuz,Claire Emson,Y. Gloria Meng,Thirumalai R. Ramalingam,Patrick Lupardus,Hans D. Brightbill,Dhaya Seshasayee,Yan Wu,Joseph R. Arron

Abstract:Transforming growth factor-beta (TGF beta) is a key driver of fibrogenesis. Three TGF beta isoforms (TGF beta 1, TGF beta 2, and TGF beta 3) in mammals have distinct functions in embryonic development; however, the postnatal pathological roles and activation mechanisms of TGF beta 2 and TGF beta 3 have not been well characterized. Here, we show that the latent forms of TGF beta 2 and TGF beta 3 can be activated by integrin-independent mechanisms and have lower activation thresholds compared to TGF beta 1. Unlike TGFB1, TGFB2 and TGFB3 expression is increased in human lung and liver fibrotic tissues compared to healthy control tissues. Thus, TGF beta 2 and TGF beta 3 may play a pathological role in fibrosis. Inducible conditional knockout mice and anti-TGF beta isoform-selective antibodies demonstrated that TGF beta 2 and TGF beta 3 are independently involved in mouse fibrosis models in vivo, and selective TGF beta 2 and TGF beta 3 inhibition does not lead to the increased inflammation observed with pan-TGF beta isoform inhibition. A cocrystal structure of a TGF beta 2-anti-TGF beta 2/3 antibody complex reveals an allosteric isoform-selective inhibitory mechanism. Therefore, inhibiting TGF beta 2 and/or TGF beta 3 while sparing TGF beta 1 may alleviate fibrosis without toxicity concerns associated with pan-TGF beta blockade.

TGF2 and TGF3 isoforms drive fibrotic disease pathogenesis